medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-05-84-90medsovet-1331Research ArticleУРОЛОГИЯUROLOGYКомбинированное лечение симптомов нижних мочевых путей у мужчинКасянГ. Р.

д.м.н., профессор

ХодыреваЛ. А.ДудареваА. А.ТупикинаН. В.ПушкарьД. Ю.

д.м.н., профессор

Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава РоссииRussian FederationНаучно-исследовательский институт здравоохранения и медицинского менеджмента Департамента здравоохранения г. МосквыRussian Federation201630122016058490Copyright © Касян Г.Р., Ходырева Л.А., Дударева А.А., Тупикина Н.В., Пушкарь Д.Ю., 20162016Касян Г.Р., Ходырева Л.А., Дударева А.А., Тупикина Н.В., Пушкарь Д.Ю.Касян Г.Р., Ходырева Л.А., Дударева А.А., Тупикина Н.В., Пушкарь Д.Ю.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1331

Термин «симптомы нижних мочевых путей» (СНМП) используется для описания расстройства мочеиспускания у мужчин, чаще всего связанного с доброкачественной гиперплазией предстательной железы (ДГПЖ). Однако в их развитии играют важную роль и другие факторы, включающие дисфункцию мочевого пузыря и/или уретры, такие как нейрогенная гиперактивность детрузора, снижение сократительной способности детрузора или ночная полиурия вследствие изменения функции почек, наличие болезни Паркинсона, церебральной ишемии, метаболического синдрома, инфекция нижних мочевых путей, стриктура мочеиспускательного канала, прием различных медикаментов и мн. др. В настоящее время общепризнано, что СНМП имеют мультифакториальную природу [1, 2]. Определение прямой связи между СНМП и ДГПЖ в ряде случаев представляется крайне затруднительным. Но следует помнить, что жалобы на СНМП, а не наличие ДГПЖ являются главной причиной обращения пациентов за медицинской помощью [3]. 

симптомы нижних мочевых путеймужчинымедикаментозная терапиятамсулозинсолифенацинReferencesChapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol, 2006 Apr, 49(4): 651-8.Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol, 2006 Apr, 49(4): 651-8.Chapple C. Systematic review of therapy for men with overactive bladder. Can Urol Assoc J. 2011 Oct, 5(5 Suppl 2): S143-5.Chapple C. Systematic review of therapy for men with overactive bladder. Can Urol Assoc J. 2011 Oct, 5(5 Suppl 2): S143-5.Stöhrer M, Blok B, Castro-Diaz D et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol, 2009 Jul, 56(1): 81-8.Stöhrer M, Blok B, Castro-Diaz D et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol, 2009 Jul, 56(1): 81-8.Knutson T, Edlund C, Fall M et al. BPH with coexisting overactive bladder dysfunction–an everyday urological dilemma. Neurourol Urodyn, 2001, 20(3): 237-47.Knutson T, Edlund C, Fall M et al. BPH with coexisting overactive bladder dysfunction–an everyday urological dilemma. Neurourol Urodyn, 2001, 20(3): 237-47.Sexton CC, Coyne KS, Kopp ZS. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA. BJU Int, 2009 Apr, 103(Suppl 3): 12-23.Sexton CC, Coyne KS, Kopp ZS. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA. BJU Int, 2009 Apr, 103(Suppl 3): 12-23.Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol, 2006, 50(6): 1306- 1314, discussion 1314-1315.Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol, 2006, 50(6): 1306- 1314, discussion 1314-1315.van Kerrebroeck P, Haab F, Angulo JC et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol, 2013, 64:398-407.van Kerrebroeck P, Haab F, Angulo JC et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol, 2013, 64:398-407.Oelke M, Bachmann A, Descazeaud A et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol, 2013, 64: 118-40.Oelke M, Bachmann A, Descazeaud A et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol, 2013, 64: 118-40.Bishr M, Boehm K, Trudeau V, Tian Z, Dell’Oglio P, Schiffmann J, Jeldres C, Sun M, Shariat SF, Graefen M, Saad F, Karakiewicz PI. Medi cal management of benign prostatic hyperplasia: Re sults from a population-based study. Can Urol Assoc J, 2016 Jan-Feb, 10(1-2): 55-9. doi: 10.5489/cuaj.3058.Bishr M, Boehm K, Trudeau V, Tian Z, Dell’Oglio P, Schiffmann J, Jeldres C, Sun M, Shariat SF, Graefen M, Saad F, Karakiewicz PI. Medi cal management of benign prostatic hyperplasia: Re sults from a population-based study. Can Urol Assoc J, 2016 Jan-Feb, 10(1-2): 55-9. doi: 10.5489/cuaj.3058.-. Cornu JN, Cussenot O, Haab F et al. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urology, 2010, 58: 450-6.-. Cornu JN, Cussenot O, Haab F et al. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urology, 2010, 58: 450-6.Helfand BT, Evans RM, McVary KT. A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients. Eur Urol., 2010 Apr, 57(4): 586-91.Helfand BT, Evans RM, McVary KT. A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients. Eur Urol., 2010 Apr, 57(4): 586-91.Gratzke C, Bachmann A, Descazeaud A et al. EAU Guidelines on the Assessment of Nonneurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol., 2015 Jun, 67(6): 1099- 109. doi: 10.1016/j.eururo.2014.12.038.Gratzke C, Bachmann A, Descazeaud A et al. EAU Guidelines on the Assessment of Nonneurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol., 2015 Jun, 67(6): 1099- 109. doi: 10.1016/j.eururo.2014.12.038.Kaplan SA, McCammon K, Fincher R et al. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol., 2009 Dec, 182(6): 2825-30.Kaplan SA, McCammon K, Fincher R et al. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol., 2009 Dec, 182(6): 2825-30.Masumori N, Tsukamoto T, Yanase M, Horita H, Aoki M. The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symp toms suggestive of benign prostatic obstruction. Adv Urol., 2010: 205251.Masumori N, Tsukamoto T, Yanase M, Horita H, Aoki M. The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symp toms suggestive of benign prostatic obstruction. Adv Urol., 2010: 205251.Yamaguchi 0, Kakizaki H, Homma Y et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms - ASSIST, randomized controlled study. Urology, 2011, 78: 126-33.Yamaguchi 0, Kakizaki H, Homma Y et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms - ASSIST, randomized controlled study. Urology, 2011, 78: 126-33.Van Kerrebroeck P, Haab F, Angulo JC et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol., 2013 Sep, 64(3): 398-407.Van Kerrebroeck P, Haab F, Angulo JC et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol., 2013 Sep, 64(3): 398-407.Drake MJ, Sokol R, Coyne K et al. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study. BJU Int., 2016 Jan, 117(1): 165-72.Drake MJ, Sokol R, Coyne K et al. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study. BJU Int., 2016 Jan, 117(1): 165-72.van Kerrebroeck P, Chapple C, Drogendijk T et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol., 2013 Dec, 64(6): 1003-12.van Kerrebroeck P, Chapple C, Drogendijk T et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol., 2013 Dec, 64(6): 1003-12.Drake MJ, Chapple C, Sokol R et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol., 2015 Feb, 67(2): 262-70.Drake MJ, Chapple C, Sokol R et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol., 2015 Feb, 67(2): 262-70.Lee SH, Byun SS, Lee SJ, Kim KH, Lee JY. Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study. Int Urol Nephrol., 2014, 46(3): 523-529.Lee SH, Byun SS, Lee SJ, Kim KH, Lee JY. Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study. Int Urol Nephrol., 2014, 46(3): 523-529.Shin YS, Zhang LT, Zhao C, Kim YG, Park JK. Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms. Clin Interv Aging., 2014, 9: 1021-1030.Shin YS, Zhang LT, Zhao C, Kim YG, Park JK. Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms. Clin Interv Aging., 2014, 9: 1021-1030.Yun JH, Kim JH, Kim JH et al. Can we decide the optimal initial treat ment for male lower urinary tract symptoms patients with overactive bladder by the most bothersome symptom? A randomized, prospective open-label study. Urol int., 2014, 93(3): 338-343.Yun JH, Kim JH, Kim JH et al. Can we decide the optimal initial treat ment for male lower urinary tract symptoms patients with overactive bladder by the most bothersome symptom? A randomized, prospective open-label study. Urol int., 2014, 93(3): 338-343.Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O. Effect of (R)-2-(2- aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. Pharmacol Exp Ther., 2007 May, 321(2): 642-7. Epub 2007 Feb 9.Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O. Effect of (R)-2-(2- aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. Pharmacol Exp Ther., 2007 May, 321(2): 642-7. Epub 2007 Feb 9.Cui Y, Zong H, Yang C et al. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol, 2014, 46: 275.Cui Y, Zong H, Yang C et al. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol, 2014, 46: 275.Gong M, Dong W, Huang G et al.Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin., 2015, 31(9): 1781-92.Gong M, Dong W, Huang G et al.Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin., 2015, 31(9): 1781-92.

The authors declare that there are no conflicts of interest present.